The veracity of the MIPE screen for identifying aggressive PrCa vulernerabilities was validated by the identification of various anticipated pathway targets (e.g. PI3K/mTORC, EGFR, BRD4, and tubulin35,41) and has revealed additional targets of interest (see below). This evidence concerns the gene EGFR and pure red-cell aplasia.